Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

406
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
406
Symbiosis00:58

Symbiosis

27.4K
Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
27.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying relative health impact across Gavi, the Vaccine Alliance's portfolio in 117 countries at the subregional level: a modelling study.

Lancet (London, England)·2026
Same author

Bridging the Implementation Gap in Medical AI Education: 3-Lever Framework for Concurrent Reform.

JMIR medical education·2026
Same author

Timing of the fourth dose of RTS,S/AS01 malaria vaccine in perennial settings: a modelling study.

Malaria journal·2026
Same author

Combining seasonal malaria chemoprevention with novel therapeutics for malaria prevention: a mathematical modelling study.

PLoS computational biology·2026
Same author

Barriers to the application of Health Technology Assessment (HTA) results: the case of COVID-19 vaccine deployment in Ghana.

International journal of technology assessment in health care·2026
Same author

Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.

Lancet (London, England)·2025

Related Experiment Video

Updated: Jun 2, 2025

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.3K

Therapeutic development to accelerate malaria control through intentional intervention layering.

Lydia Braunack-Mayer1,2, Narimane Nekkab1,2, Josephine Malinga3,4

  • 1Swiss Tropical and Public Health Institute, Allschwil, Switzerland.

Malaria Journal
|January 13, 2025
PubMed
Summary

Novel malaria interventions, including vaccines and drugs, offer new tools for Plasmodium falciparum control. Addressing key research gaps in outcome measurement, unique public health benefits, and population-level justification is crucial for maximizing their impact.

Keywords:
Plasmodium falciparumIntervention layeringIntervention mixingMalariaModelling

More Related Videos

Microinjection Method for Anopheles gambiae Embryos
05:39

Microinjection Method for Anopheles gambiae Embryos

Published on: July 7, 2021

4.5K
Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

2.9K

Related Experiment Videos

Last Updated: Jun 2, 2025

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.3K
Microinjection Method for Anopheles gambiae Embryos
05:39

Microinjection Method for Anopheles gambiae Embryos

Published on: July 7, 2021

4.5K
Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

2.9K

Area of Science:

  • * Malariology and Global Health
  • * Infectious Disease Prevention and Control

Background:

  • * Novel vaccines, therapeutics, and chemoprevention drugs are emerging for Plasmodium falciparum malaria.
  • * These tools can accelerate malaria control, especially in moderate to low transmission settings.
  • * Effectiveness of new tools is limited by current research gaps.

Purpose of the Study:

  • * To identify critical gaps hindering the full potential of new malaria medical interventions.
  • * To propose a framework for evaluating and integrating novel tools into existing malaria control programs.

Main Methods:

  • * Perspective piece analyzing current limitations in malaria intervention research.
  • * Discussion of three key areas: outcome measurement, unique public health benefits, and population-level justification.
  • * Review of existing literature and clinical development strategies for malaria control.

Main Results:

  • * Gap 1: Burden reduction outcomes may not fully capture accelerated malaria control goals.
  • * Gap 2: Novel tools must offer unique public health outcomes beyond incremental improvements.
  • * Gap 3: Determining population-level benefits versus individual outcomes is essential for multi-tool programs.

Conclusions:

  • * Malaria research must refine outcome metrics to align with accelerated control objectives.
  • * New interventions should target unmet needs and specific parasite life cycle stages.
  • * A balanced perspective considering both individual and population benefits is vital for successful intervention layering.